Coronary In-Stent Restenosis: JACC State-of-the-Art Review
The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …
substantially improved the efficacy and safety of percutaneous coronary interventions …
Contemporary issues in chronic total occlusion percutaneous coronary intervention
L Azzalini, D Karmpaliotis, R Santiago… - Cardiovascular …, 2022 - jacc.org
Remarkable progress has been achieved in chronic total occlusion (CTO) percutaneous
coronary intervention (PCI) in recent years, with refinement of the indications and technical …
coronary intervention (PCI) in recent years, with refinement of the indications and technical …
[HTML][HTML] Management of in-stent restenosis
In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous
coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI …
coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI …
Cardiac intensive care unit: where we are in 2023
A Bouchlarhem, Z Bazid, N Ismaili… - Frontiers in …, 2023 - frontiersin.org
Cardiac intensive care has been a constantly evolving area of research and innovation
since the beginning of the 21st century. The story began in 1961 with Desmond Julian's …
since the beginning of the 21st century. The story began in 1961 with Desmond Julian's …
Association between LDL/HDL ratio and in-stent restenosis in patients with acute coronary syndrome after stent implantation
Y Fang, M Lin, L Chen, C Yang, A Liu - Biomarkers in Medicine, 2022 - Taylor & Francis
Background: The relationship between LDL/HDL ratio and in-stent restenosis in acute
coronary syndrome is unknown. Methods: This observational study recruited 256 patients …
coronary syndrome is unknown. Methods: This observational study recruited 256 patients …
Clinical outcome of paclitaxel-coated balloon angioplasty versus drug-eluting stent implantation for the treatment of coronary drug-eluting stent in-stent chronic total …
Y Zhang, Z Wu, S Wang, T Liu, J Liu - Cardiovascular Drugs and Therapy, 2023 - Springer
Aims In-stent chronic total occlusion (IS-CTO) represents a unique challenge for
percutaneous coronary intervention. Whether the optimal treatment for IS-CTO is angioplasty …
percutaneous coronary intervention. Whether the optimal treatment for IS-CTO is angioplasty …
Contemporary percutaneous interventions for coronary chronic total occlusions
I Xenogiannis, AN Pavlidis… - Frontiers in Cardiovascular …, 2024 - frontiersin.org
On the contrary, the randomized REVASC study failed to meet its primary endpoint which
was the improvement of segmental wall thickening in the territory of the corresponding CTO …
was the improvement of segmental wall thickening in the territory of the corresponding CTO …
[HTML][HTML] Recent Advances in the Treatment of Coronary In-Stent Restenosis
In-stent restenosis (ISR) remains the predominant cause of stent failure and the most
common indication for repeat revascularization. Despite technological advances in stent …
common indication for repeat revascularization. Despite technological advances in stent …
Instent CTO—What Is the Best Treatment Strategy?
M Sahyouni, GA Stouffer - Cardiovascular Drugs and Therapy, 2024 - Springer
Instent chronic total occlusion (IS-CTO) is defined as complete occlusion for at least 3
months at a stent site or within 5 mm proximal or distal to the stent. The pathophysiology of …
months at a stent site or within 5 mm proximal or distal to the stent. The pathophysiology of …
Comparison of Percutaneous Coronary Intervention-Related Adverse Cardiac Outcomes in Patients With in-stent vs de novo Chronic Total Occlusion: A Systematic …
Contemporary literature reveals a range of cardiac complications in patients who receive the
percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). This study …
percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). This study …